1-3 of 3
Ying Mao
Close
Sort by
Journal Articles

Phase 1 Trial of Orelabrutinib in Combination with Rituximab, Methotrexate, and Dexamethasone in Patients with Newly Diagnosed Primary CNS Lymphoma Implementing Bayesian Design for Dose-Seeking

Yan Yuan, Qian Wang, Dongxiao Zhuang, Tianling Ding, Hong Chen, Fengping Zhu, Kang Zheng, Rui Feng, Jiajun Zheng, Xiaoluo Zhang, Zunguo Du, Ping Zhu, Jinsong Wu, Ying Mao, Tong Chen
Journal: Blood
Blood (2023) 142 (Supplement 1): 6225.
https://doi.org/10.1182/blood-2023-181427
Published: 2023
Journal Articles

Preliminary Result of Phase 1 Trial of Orelabrutinib in Combination with Rituximab, Methotrexate, and Dexamethasone in Patients with Newly Diagnosed Primary CNS Lymphoma Implementing Bayesian Design for Dose-Seeking

Yan Yuan, Qian Wang, Dongxiao Zhuang, Tianling Ding, Hong Chen, Fengping Zhu, Kang Zheng, Rui Feng, Jiajun Zheng, Xiaoluo Zhang, Zunguo Du, Ping Zhu, Jinsong Wu, Ying Mao, Tong Chen
Journal: Blood
Blood (2022) 140 (Supplement 1): 6629–6630.
https://doi.org/10.1182/blood-2022-159309
Published: 2022
Journal Articles

Impact of Hematologists' Personality and Behavioral Traits on Medical Decision-Making for Elderly Acute Myeloid Leukemia: A National Study in China

Xia Wu, MD, Yi-Nan Jiang, Yue-Lun Zhang, Jia Chen, Yue-ying Mao, Lu Zhang, MD, Dao-Bin Zhou, Xinxin Cao, MD, Jian Li, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19.
https://doi.org/10.1182/blood-2020-135957
Published: 2020